December 15th, 2015

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

News releases from Remedy Pharmaceuticals

Biogen Acquires Remedy Pharmaceuticals’ Late-Stage Drug CIRARA™
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving treatments to people affected by central nervous system diseases and injuries, today announced that... 
Tickers BIIB
From Business Wire News Releases
Remedy Pharmaceuticals’ CIRARA Granted Orphan Drug Designation For Treatment of Severe Cerebral Edema Caused By Acute Ischemic Stroke
Remedy Pharmaceuticals announces that the FDA has granted Orphan Drug Designation for its investigational drug, CIRARA, for treatment of severe cerebral edema in patients with acute ischemic stroke. 
From Business Wire News Releases
David Epstein Joins as Special Advisor to Remedy Pharmaceuticals
Remedy Pharmaceuticals announces David Epstein, previously Division Head and CEO of Novartis Pharmaceuticals, has joined as special advisor to Remedy's board of directors. 
From Business Wire News Releases
Remedy Pharmaceuticals’ Edema and Neuro-inflammation Advisory Board Provides Guidance on Opportunities in CNS Conditions
Remedy Pharmaceuticals, a privately-held phase 3-ready pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system related edema, today... 
From Business Wire News Releases
Roger Ulrich Joins Board of Remedy Pharmaceuticals
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today... 
Tickers ABBV AZN GILD MRK
From Business Wire News Releases
Remedy Pharmaceuticals Receives FDA Fast Track Designation for CIRARA™
Remedy Pharmaceuticals, a privately-held pharmaceutical company focused on bringing life-saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today... 
From Business Wire News Releases
Remedy Pharmaceuticals Announces Two Oral Presentations on Results of CNS-Related Edema Trial At Annual American Academy of Neurology Meeting
Remedy announces that results of its Phase 2 trial of CIRARA™ for preventing edema in large hemispheric infarctions will be presented during two oral presentations at the 68th Annual AAN meeting. 
From Business Wire News Releases
Remedy Pharmaceuticals Issues First Quarter 2016 Report
Remedy Pharmaceuticals announces the issuance of its end-of-first-quarter report. 
From Business Wire News Releases
Remedy Pharmaceuticals Appoints Thomas MacAllister as Vice President of Research and Development and General Counsel
Remedy Pharmaceuticals announces appointment of Thomas MacAllister as Vice President of Research and Development, and General Counsel. 
From Business Wire News Releases
Remedy Pharmaceuticals Announces Successful Completion of End-of-Phase 2 Meeting With FDA on a Novel Drug Treatment for CNS-Related Edema
Remedy Pharmaceuticals, a privately-held, pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema, today... 
From GlobeNewswire News Releases
Remedy Pharmaceuticals Announces Additional Results From Phase 2 CNS-Related Edema Study of CIRARA™ Presented at International Stroke Conference
Remedy Pharmaceuticals, a privately-held, phase 3-ready pharmaceutical company focused on bringing life saving hospital-based treatment to people affected by central nervous system (CNS) related edema,... 
From GlobeNewswire News Releases
Remedy Pharmaceuticals Announces FDA Orphan Drug Designation in Two CNS Indications
Investigational Drug CIRARA™ Receives Orphan Drug Designation in Both Acute Subarachnoid Hemorrhage and Acute Spinal Cord Injury 
From GlobeNewswire News Releases
Remedy Pharmaceuticals Announces Acceptance of Two Oral Presentations on Phase 2 Results of CIRARA™ for CNS-Related Edema at ISC 2016
Presentations by Principal Investigators at Yale University and Massachusetts General Hospital 
From GlobeNewswire News Releases
Remedy Pharmaceuticals Completes $9 Million Financing
Remedy Pharmaceuticals completes $9 million financing 
Tickers DD
From Business Wire News Releases
Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting
Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting 
From Business Wire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

More ways to get to us

Medicine Hat News Twitter Twitter
Medicine Hat News Facebook Facebook
Medicine Hat News YouTube YouTube
Medicine Hat News Tumblr Tumblr

About Us

Contact the Medicine Hat News

3257 Dunmore Rd SE
Medicine Hat, AB T1B 3R2

[P] 403.527.1101
[F] 403.528.5696

Print Advertising: 403.528.5650
National Advertising: 403.528.5766
Online Advertising: 403.528.5698
Classifieds: 403.526.7653

© 1996-2015 The Medicine Hat News, A Division of Continental Newspapers Canada Ltd.